Sign In
Buy BCDA
$0.82
+0.0531 (+6.89%)
At Close: Jul 31, 2026
SUNNYVALE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
12:56pm, Thursday, 16'th Nov 2023
SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
12:47pm, Wednesday, 15'th Nov 2023
The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
07:15am, Tuesday, 14'th Nov 2023
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript
08:08pm, Wednesday, 08'th Nov 2023
BioCardia, Inc. (NASDAQ:BCDA ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and Chief Executive Officer
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
07:32pm, Wednesday, 08'th Nov 2023
BioCardia, Inc. (BCDA) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023
05:04pm, Wednesday, 01'st Nov 2023
SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
12:47pm, Thursday, 12'th Oct 2023
BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial st
BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study
12:01pm, Wednesday, 06'th Sep 2023
Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the primary endpoint for the treatment of heart failure.
BioCardia shares slide on disappointing interim data from heart therapy trial
09:31am, Tuesday, 05'th Sep 2023
BioCardia shares fell more than 20% in pre-market trade on Tuesday after the biopharmaceutical firm revealed that its Phase 3 trial of CardiAMP cell therapy for heart failure was unlikely to meet its
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
07:44pm, Wednesday, 09'th Aug 2023
BioCardia, Inc. (BCDA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.14 per share a year ago.
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
08:00pm, Wednesday, 03'rd May 2023
SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript
10:38pm, Wednesday, 29'th Mar 2023
BioCardia, Inc. (NASDAQ:BCDA ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantg
